株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

コンパニオン診断 (CDx) の世界市場:2016-2026年

The Companion Diagnostics (CDx) Market Forecast 2016-2026: Leading Companies, Trends and Developments in the Growing Theranostics Market

発行 Visiongain Ltd 商品コード 210220
出版日 ページ情報 英文 192 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.80円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
コンパニオン診断 (CDx) の世界市場:2016-2026年 The Companion Diagnostics (CDx) Market Forecast 2016-2026: Leading Companies, Trends and Developments in the Growing Theranostics Market
出版日: 2016年03月31日 ページ情報: 英文 192 Pages
概要

2020年、世界のコンパニオン診断の市場は105億ドルの規模に達し、2026年まで収益は安定して成長すると予測されています。この市場成長を促進する要因として、細胞および組織研究の進歩、規制状況の改善、各地での政府援助の強化、そしてまだ満たされない医療ニーズ分野における新たな治療法がいくつか発表されたことなどが挙げられます。

当レポートでは、コンパニオン診断 (CDx) の世界市場について調査し、個別化医療および体外診断検査 (IVD検査) におけるコンパニオン診断の位置付け、コンパニオン診断の市場規模の推移と予測、コンパニオン診断のひとつとしてのセラノスティクスの成長、主要国の動向、主な上市済み製品とパイプラインにおける提携の動向、コンパニオン診断開発のビジネスモデル、競合環境、主要企業のプロファイルなどをまとめています。

第1章 レポート概要

第2章 コンパニオン診断:イントロダクション

  • 個別化医療の基盤
  • 個別化医療:患者治療のパラダイムの変化
  • 体外診断検査 (IVD検査)
    • コンパニオン診断:IVDのひとつのタイプ
    • コンパニオン診断とセラノスティクスの違い
    • バイオマーカーとコンパニオン診断
    • ゲノムバイオマーカー
    • 癌のゲノムバイオマーカー
  • 関連法規制
  • コンパニオン診断の同時期の開発の奨励

第3章 世界のコンパニオン診断市場

  • 範囲と限界
  • 世界のコンパニオン診断市場:実績
  • 世界のコンパニオン診断市場:売上予測
  • コンパニオン診断:他のIVD部門を上回る成長
  • コンパニオン診断:IVD市場でシェアを伸ばす
  • 部門別市場の実績
  • セラノスティクス:コンパニオン診断の中の最速成長部門
  • コンパニオン診断の主要部門のシェアの変化の見通し

第4章 コンパニオン診断:主要国市場の予測

  • 主要国市場:主要3市場が主導する現状
  • 主要国の売上予測
    • 市場シェアの変化の予測
  • 米国の売上予測
  • EU5カ国の実績
    • 売上予測
    • シェアの変化
    • ドイツの売上予測
    • フランスの売上予測
    • イタリアの売上予測
    • スペインの売上予測
    • 英国の売上予測
  • 日本の売上予測
  • 中国の売上予測
  • インドの売上予測
  • ブラジルの売上予測
  • ロシアの売上予測
  • 韓国の売上予測
  • その他の売上予測

第5章 コンパニオン診断市場:上市済み製品とパイプラインの提携

  • バイオマーカー:コンパニオン診断開発の中心
  • 米国FDA承認済みコンパニオン診断検査
  • 癌の診断:コンパニオン診断のR&Dパイプラインの対象として引き続き主流
  • 高額な癌治療がCDxの開発を推進
  • コンパニオン診断/製薬事業者の提携

第6章 コンパニオン診断:ビジネスモデルとステークホルダー

  • コンパニオン診断開発のビジネスモデル
  • コンパニオン診断市場への参入の推進因子
  • コンパニオン診断市場に影響力を持つステークホルダー
  • コンパニオン診断市場における競合状況

第7章 主要企業

  • Roche:診断市場の世界的リーダー
  • Qiagen N.V.:製薬事業者にとってのCDxの主要な提携先
  • Abbott Molecular:確立された競合事業者
  • Agilent Technologies (Dako)
  • Myriad Genetics
  • BioMerieux
  • Thermo Fisher Scientific

第8章 定量分析

  • SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • ポーターのファイブフォース分析

第9章 総論

  • 概要
  • セラノスティクス:急成長の市場
  • コンパニオン診断の主要企業
  • 製薬/診断会社との提携モデル
  • コンパニオン診断を推進する主要治療領域としての癌
  • コンパニオン診断市場の商業的成長推進因子
  • コンパニオン診断市場の商業的成長阻害因子
  • まとめ

第10章 用語集

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0104

What can be expected from the Companion Diagnostics market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 192-page report provides 127 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole companion diagnostics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

The report also includes will find revenue forecasts to 2026 for the following submarkets in the companion diagnostics market:

  • Theranostics
  • Other Companion Diagnostics

Additionally, this report includes a forecast to 2026 for the global in vitro diagnostics market.

The report also includes will find revenue forecasts to 2026 for the following national and regional markets for companion diagnostics:

  • US
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Japan
  • China
  • India
  • Russia
  • Brazil
  • South Korea

The report provides detailed profiles of key companies operating within the companion diagnostics market:

  • F. Hoffmann-La Roche Ltd
  • Qiagen N.V.
  • Abbott Laboratories
  • Agilent Technologies
  • Myriad Genetics
  • bioMerieux
  • Thermo Fisher Scientific

Leading companies and potential for market growth

Overall revenue for the Companion Diagnostics market will reach $10.5bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain's analysis of 7 leading companies, including these:

  • F. Hoffmann-La Roche Ltd
  • Qiagen N.V.
  • Abbott Laboratories
  • Agilent Technologies
  • Myriad Genetics
  • bioMerieux
  • Thermo Fisher Scientific

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Historic revenue, analysis and discussion of company performance over the past 5 years
  • Analysis of major products currently on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the companion diagnostics industry?

Our new report discusses issues and events affecting the companion diagnostics market. You will find discussions, including qualitative analyses:

  • Highly diverse market needing strong knowledge of key therapeutic indications
  • Changing regulatory landscape challenging new entrants and major market players alike
  • Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Companion Diagnostics: Market Forecast 2016-2026 report helps you

In summary, our 192-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for the Companion Diagnostics market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2026 for each major submarket - discover prospects for leading companion diagnostics products in the following areas: theranostics and other companion diagnostics.
  • Revenue forecasts to 2026 for twelve leading national markets - US, Germany, France, Italy, Spain, UK, Japan, China, India, Russia, Brazil and South Korea
  • Assessment of 7 leading companies - analysis of products, revenue, mergers & acquisitions, sales by region and products
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the companion diagnostics market and leading companies. You will find data, trends and predictions. Please order our report now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. The Companion Diagnostics Market Overview
  • 1.2. Companion Diagnostics Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports
  • 1.10. About Visiongain

2. Introduction to Companion Diagnostics

  • 2.1. The Foundation of Personalised Medicine
  • 2.2. Personalised Medicine: Changing the Patient Treatment Paradigm
  • 2.3. In Vitro Diagnostic (IVD) Tests
    • 2.3.1. Companion Diagnostics: A Type of IVD
    • 2.3.2. Differences between Companion Diagnostics and Theranostics
    • 2.3.3. Biomarkers to Companion Diagnostics
    • 2.3.4. Genomic Biomarkers
    • 2.3.5. Genomic Oncology Biomarkers
  • 2.4. Regulations in the Companion Diagnostics Market
    • 2.4.1. FDA's Final Guidance on Companion Diagnostics
    • 2.4.2. LDTs: A Changing Landscape
  • 2.5. Encouraging the Contemporaneous Development of Companion Diagnostics

3. The World Companion Diagnostics Market, 2016-2026

  • 3.1. Scope and Limitations
  • 3.2. The Global Companion Diagnostics Market, 2014 and 2015
  • 3.3. The Global Companion Diagnostics Market Sales Forecast, 2016-2026
  • 3.4. Companion Diagnostics: Growth Outpacing the Rest of the IVD Market
  • 3.5. Companion Diagnostics: Increasing Market Share of the IVD Market
  • 3.6. The Companion Diagnostics Market by Submarket, 2014
  • 3.7. Theranostics: Fastest Growing Segment of the CDx Market
  • 3.8. Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2015-2025

4. Leading National Markets for Companion Diagnostics, 2016-2026

  • 4.1. The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2014 & 2015
  • 4.2. The Leading National Markets for Companion Diagnostics Sales Forecast, 2016-2026
    • 4.2.1. Changing Market Shares of Leading National Markets, 2016-2026
  • 4.3. The US Companion Diagnostics Market Sales Forecast, 2016-2026
    • 4.3.1. The US Will Continue to Dominate the Market
  • 4.4. The EU5 Companion Diagnostics Sales Market, 2014
    • 4.4.1. The EU5 Companion Diagnostics Market Sales Forecast, 2016-2026
    • 4.4.2. Changing Market Shares of the EU5 Companion Diagnostics Market
    • 4.4.3. The German Companion Diagnostics Market Sales Forecast, 2016-2026
    • 4.4.4. The French Companion Diagnostics Market Sales Forecast, 2016-2026
    • 4.4.5. The Italian Companion Diagnostics Market Sales Forecast, 2016-2026
    • 4.4.6. The Spanish Companion Diagnostics Market Sales Forecast, 2016-2026
    • 4.4.7. The UK Companion Diagnostics Market Sales Forecast, 2016-2026
  • 4.5. The Japanese Companion Diagnostics Market Sales Forecast, 2016-2026
    • 4.5.1. Japan's Medical Technology Regulatory Process Reducing Time to Market
  • 4.6. The Chinese Companion Diagnostics Market Sales Forecast, 2016-2026
    • 4.6.1. Cancer Rates will Drive Adoption of Companion Diagnostic Tests
  • 4.7. The Indian Companion Diagnostics Market Sales Forecast, 2016-2026
  • 4.8. The Brazilian Companion Diagnostics Market Sales Forecast, 2016-2026
  • 4.9. The Russian Companion Diagnostics Market Sales Forecast, 2016-2026
  • 4.10. The South Korean Companion Diagnostics Market Sales Forecast, 2016-2026
  • 4.11. The Rest of the World Companion Diagnostics Market Sales Forecast, 2016-2026

5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships

  • 5.1. Biomarkers: At the Forefront of Companion Diagnostics Development
  • 5.2. US FDA Approved Companion Diagnostic Tests, 2016
  • 5.3. Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics
  • 5.4. Expensive Cancer Therapies Encourages the Development of CDx
  • 5.5. Companion Diagnostic/Pharma Partnerships, 2013-2014

6. Business Models and Stakeholders in the Companion Diagnostics Market

  • 6.1. Business Models for the Development of Companion Diagnostics
    • 6.1.1. The Partnership Model is the Most Practiced Method
    • 6.1.2. The Stand-Alone Model: Licensing an IP
    • 6.1.3. The One Stop Shop Model: An Approach by Big Pharma
    • 6.1.4. Using Contract Diagnostics Organisations (CDO): An Emerging Trend
  • 6.2. Factors Driving Companies to Enter the Companion Diagnostics Market
  • 6.3. Stakeholders Influencing the Companion Diagnostics Market
    • 6.3.1. Pharmaceutical Companies and Diagnostic Manufacturers
    • 6.3.2. Regulatory Authorities
    • 6.3.3. Testing Laboratories
    • 6.3.4. Physicians and Patients
    • 6.3.5. Payers
  • 6.4. Companion Diagnostics Competitive Landscape, 2016

7. Leading Companies in the Companion Diagnostics Market 2015

  • 7.1. Roche: Global Diagnostics Leader
    • 7.1.1. Ventana Medical Systems (Roche)
    • 7.1.2. Sales and Recent Performance Analysis, 2014
    • 7.1.3. Roche Diagnostics by Region, 2014
    • 7.1.4. Roche: Internal Growth
    • 7.1.5. Approval of Tarceva and Cobas EGFR Mutation Test
    • 7.1.6. Roche's Portfolio of Companion Diagnostic Project Pipeline and Marketed Companion Diagnostics, 2015
    • 7.1.7. Ventana Companion Diagnostics: Robust New Prototype Assays
    • 7.1.8. Recent Companion Diagnostic External Collaborations, 2014-2015
      • 7.1.8.1. Ventana/Genmab
      • 7.1.8.2. Ferring/ Roche: CDx Development for Infertility Treatment
      • 7.1.8.3. MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials
      • 7.1.8.4. Merck/Ventana: CDx for an Undisclosed Target
      • 7.1.8.5. AstraZeneca/Roche: CDx to Support Target Drug AZD9291
      • 7.1.8.6. Boehringer Ingelheim/Roche
      • 7.1.8.7. ImmunoGen/ Ventana
      • 7.1.8.8. Foundation Medicine/Roche
    • 7.1.9. Roche: Major M&A Activity and Strategic Partnerships Strengthen Position as Diagnostic Market Leader
      • 7.1.9.1. Genia Acquisition to Strengthen DNA Sequencing Capabilities
      • 7.1.9.2. IQuum Acquisition Allows Movement into POC MDx Market
      • 7.1.9.3. Seragon Acquisition Strengthens Leading Position in Oncology
      • 7.1.9.4. Santaris Acquisition Enchances Roche's Position in RNA-Targeted Drugs Market
      • 7.1.9.5. Bina Acquisition Brings Big Data Solution to Support NGS Development
      • 7.1.9.6. Dutalys Acquisition Enhances Roche's mAB Portfolio
      • 7.1.9.7. Ariosa Acquisition Adds NIPT to Diagnostic Portfolio
      • 7.1.9.8. Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
      • 7.1.9.9. Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
      • 7.1.9.10. GENEWEAVE and Kapa Acquisitions Help Cement Roche's Position as the Market Leader
  • 7.2. Qiagen N.V.: Leading CDx Collaborator with Pharmaceutical Companies
    • 7.2.1. Sales and Recent Performance Analysis, 2010-2015
    • 7.2.2. Qiagen Sales By Region
    • 7.2.3. Companion Diagnostics Collaboration Agreements with Pharma, 2015
      • 7.2.3.1. Collaboration with Eli Lilly
      • 7.2.3.2. Collaboration with AstraZeneca
      • 7.2.3.3. Collaboration with Astellas Pharma
      • 7.2.3.4. Collaboration with Novartis
      • 7.2.3.5. Collaboration with Array BioPharma
      • 7.2.3.6. Collaboration with Protagen
  • 7.3. Abbott Molecular: An Established Competitor
    • 7.3.1. Sales and Recent Performance Analysis, 2012-2015
    • 7.3.2. Abbott Molecular: Expansive Oncology Biomarker Pipeline
    • 7.3.3. Recent Activity and Collaborations
      • 7.3.3.1. Collaboration with Merck
      • 7.3.3.2. Collaborative Efforts with Idera
      • 7.3.3.3. Collaboration with AstraZeneca
  • 7.4. Agilent Technologies (Dako)
    • 7.4.1. Life Sciences and Diagnostics Business
    • 7.4.2. Agilent Life Sciences and Diagnostics, Sales and Recent Performance Analysis, 2015
    • 7.4.3. Agilent: Next Generation Sequencing Platforms
    • 7.4.4. Recent Companion Diagnostic Collaborations
      • 7.4.4.1. Agilent/ Merck: Several Cancer Collaborations
      • 7.4.4.2. Agilent/Pfizer: An Ongoing Collaboration
      • 7.4.4.3. Agilent/Bristol-Myers Squibb
  • 7.5. Myriad Genetics
    • 7.5.1. Acquisition of Myriad RBM: Increases the Company's Market Share of Companion Diagnostics
    • 7.5.2. Companion Diagnostic Service Offerings
    • 7.5.3. Sales and Recent Performance Analysis, 2013-2014
      • 7.5.3.1. myRisk: Next Generation Hereditary Cancer Testing
    • 7.5.4. Myriad Genetics Recent Collaborations
      • 7.5.4.1. Myriad/AstraZeneca: Premarket Approval Application
      • 7.5.4.2. Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market
      • 7.5.4.3. Myriad/ TESARO Companion Collaboration
      • 7.5.4.4. Collaboration with AbbVie
  • 7.6. BioMérieux
    • 7.6.1. Sales and Recent Performance Analysis, 2010-2015
    • 7.6.2. Sales by Region, 2014
    • 7.6.3. Sales by Technology, 2015
    • 7.6.4. Companion Diagnostics: Recent M&A Activity & Collaboration
      • 7.6.4.1. Collaboration with Gilead Sciences
      • 7.6.4.2. Collaboration with Ipsen
      • 7.6.4.3. Collaboration with Merck
      • 7.6.4.4. Collaborations with GSK and Novartis
      • 7.6.4.5. Mergers, Acquisitions and Collaborations
    • 7.6.5. bioTheranostics: Subsidiary for Oncology Diagnostics
  • 7.7. Thermo Fisher Scientific
    • 7.7.1. Sales and Recent Performance Analysis, 2013-2014
      • 7.7.1.1. Thermo Fisher Scientific Sales by Region, 2015
    • 7.7.2. Recent Collaborations and Acquisitions
      • 7.7.2.1. Acquisition of Life Technologies
      • 7.7.2.2. Acquisition of Prionics
      • 7.7.2.3. Acquisition of Advanced Scientifics, Inc.
      • 7.7.2.4. Acquisition of Alfa Aesar
      • 7.7.2.5. Affymetrix: Thermo Fisher's Next Target
      • 7.7.2.6. Thermo Fisher: Developing a ‘Universal' Companion Diagnostics Using Next Generation Sequencing
      • 7.7.2.7. Thermo Fisher: Life Technologies Collaborates with Merck Serono
      • 7.7.2.8. Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC

8. Qualitative Analysis of the Companion Diagnostics Market, 2016-2026

  • 8.1. SWOT Analysis of the Companion Diagnostics Market
  • 8.2. Strengths
    • 8.2.1. A CDx Strategy Decreases the Length of Approval Process
    • 8.2.2. Premium Prices for Companion Diagnostics
    • 8.2.3. A CDx Development Strategy Can Generate More Effective Drugs
    • 8.2.4. Therapeutics Tied with CDx can have Safer Profiles
    • 8.2.5. Reducing the Cost of Healthcare
    • 8.2.6. Increased Regulatory Scrutiny on Marketed Drugs
    • 8.2.7. Targeted Therapies Will Drive the CDx Market
  • 8.3. Weaknesses
    • 8.3.1. Reimbursement Challenges
    • 8.3.2. Lack of Clear Regulatory Guidelines
    • 8.3.3. Capital Intensity is High
  • 8.4. Opportunities
    • 8.4.1. Fast-growing Emerging Markets
    • 8.4.2. Next Generation Sequencing
    • 8.4.3. Many New CDx/ Pharma Company Partnerships
  • 8.5. Threats
    • 8.5.1. Complex Business Models and Business Partnerships
    • 8.5.2. Medical Device Excise Tax
  • 8.6. Porter's Five Forces Analysis of the Companion Diagnostics Market
    • 8.6.1. Rivalry Among Competitors [High]
    • 8.6.2. Power of Suppliers [High]
    • 8.6.3. Power of Buyers [Medium]
    • 8.6.4. Threat of New Entrants [Medium]
    • 8.6.5. Threat of Substitutes [High]

9. Conclusions

  • 9.1. Overview
  • 9.2. Theranostics: A Fast Growing Market
  • 9.3. Leading Companion Diagnostic Companies
  • 9.4. Pharmaceutical/Diagnostic Partnership Model
  • 9.5. Oncology is the Leading Therapy Area Driving Companion Diagnostics
  • 9.6. Commercial Drivers of the Companion Diagnostics Market
  • 9.7. Commercial Restraints of the Companion Diagnostics Market
  • 9.8. Concluding Remarks

10. Glossary

Appendix

  • Visiongain's Bespoke Research Service
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 1.1: The CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2014-2026
  • Table 1.2: The CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2020-2026
  • Table 2.1: Examples of Clinically Relevant Cancer Biomarkers, 2016
  • Table 3.1: The World IVD Market: Revenue ($bn) and Market Share (%) by Segment, 2014
  • Table 3.2: The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 3.3: The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 3.4: The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 3.5: The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 3.6: CDx Market Share (%) in the IVD Market, 2014, 2020, 2026
  • Table 3.7: The World Companion Diagnostics Market: Revenue ($bn) and Market Share (%) by Submarket, 2014
  • Table 3.8: The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%) and CAGR (%), by Submarket, 2014-2020
  • Table 3.9: The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%) and CAGR (%), by Submarket, 2020-2026
  • Table 3.10: Revenue ($bn) and Market Share (%) of Submarkets in the CDx Market, 2014, 2020, 2026
  • Table 4.1: The Leading National Markets for CDx: Sales ($m), Market Share (%), 2014
  • Table 4.2: The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2020
  • Table 4.3: The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2020-2026
  • Table 4.4: Revenue ($bn) and Market Share (%) of the National Markets in the CDx Market, 2014, 2020, 2026
  • Table 4.5: The US CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2014-2020
  • Table 4.6: The US CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2020-2026
  • Table 4.7: The EU5 CDx Market Forecast: Revenue ($bn) and Market Share (%), 2014
  • Table 4.8: The EU5 Companion Diagnostic National Market Forecasts: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 4.9: The EU5 Companion Diagnostic National Market Forecasts: Revenues ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 4.10: Market Share (%) of Each EU5 Region in the CDx Market, 2014, 2020, 2026
  • Table 4.11: The German CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 4.12: The German CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 4.13: The French CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 4.14: The French CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 4.15: The Italian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 4.16: The Italian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Table 4.17: The Spanish CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 4.18: The Spanish CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 4.19: The UK CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 4.20: The UK CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 4.21: The Japanese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2014-2020
  • Table 4.22: The Japanese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2020-2026
  • Table 4.23: The Chinese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 4.24: The Chinese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 4.25: The Indian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 4.26: The Indian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 4.27: The Brazilian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 4.28: The Brazilian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 4.29: The Russian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 4.30: The Russian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 4.31: The South Korean CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 4.32: The South Korean CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 4.33: The Rest of the World CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
  • Table 4.34: The Rest of the World CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 5.1: List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2016
  • Table 5.1: (Cont'd) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2016
  • Table 5.1: (Cont'd) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2016
  • Table 5.1: (Cont'd) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2016
  • Table 5.1: (Cont'd) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2016
  • Table 5.2: List of Cleared or Approved Companion Diagnostic Devices and Their Complementary Therapeutic Drug, 2015
  • Table 5.3: List of CDx Diagnostic/Pharma Partnerships, 2013-2014
  • Table 6.1: List of Companies in the Companion Diagnostics Market, 2016
  • Table 6.1: (Cont'd) List of Companies in the Companion Diagnostics Market, 2016
  • Table 7.1: Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2014
  • Table 7.2: Roche Diagnostics: Revenue ($bn), Revenue Shares (%) by Region, 2014
  • Table 7.3: Roche: Major Companion Diagnostic Projects, 2015
  • Table 7.4: Roche Diagnostics: List of Marketed Companion Diagnostics, 2015
  • Table 7.5: Qiagen: Revenue ($bn), Net Income ($bn) and Profit Margin, 2010-2015
  • Table 7.6: Qiagen: Revenue ($m), Revenue Share (%) by Geography, 2012-2015
  • Table 7.7: Abbott: Revenue ($bn) by Reported Segment, 2012-2015
  • Table 7.8: Abbott Molecular: Biomarker Pipeline, 2015
  • Table 7.9: Agilent Technologies: Revenue ($bn) by Business Segment 2013-2015
  • Table 7.10: Myriad Genetics: Biomarker Product Portfolio, 2015
  • Table 7.11: Myriad Genetics: Revenue ($bn), and Revenue Shares (%) by Sector, 2013-2015
  • Table 7.12: bioMérieux : Revenue (€bn), ($bn) and AGR (%), 2010-2015
  • Table 7.13: bioMérieux: Revenue ($m) and Revenue Change (%) by Region, 2014-2015
  • Table 7.14: bioMérieux: Revenue ($bn) and Revenue Change (%) by Technology, 2014-2015
  • Table 7.15: Thermo Fisher Scientific: Revenue Sales ($bn), AGR (%) by Business Sector, 2012-2015
  • Table 7.16: Thermo Fisher Scientific: Revenue ($bn), Revenue Share (%) by Geography, 2013-2015
  • Table 8.1: SWOT Analysis of the Companion Diagnostics Market, 2016-2026
  • Table 9.1: Theranostics and Other In Vitro Diagnostics: Global Sales Forecast ($bn), 2014, 2020 and 2026

List of Figures

  • Figure 1.1: Companion Diagnostics: Overview of Submarkets
  • Figure 2.1: Development of Biomarkers into Companion Diagnostics, 2015
  • Figure 3.1: The World IVD Market: Market Share (%) in the IVD Market, 2014
  • Figure 3.2: The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
  • Figure 3.3: The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
  • Figure 3.4: The World CDx Market Share (%) in the IVD Market, 2020
  • Figure 3.5: The World CDx Market Share (%) in the IVD Market, 2026
  • Figure 3.6: The World Companion Diagnostics Market: Market Share (%) by Submarket, 2014
  • Figure 3.7: The World CDx Market by Submarket: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 3.8: The World CDx Market Share (%) in the IVD Market, 2020
  • Figure 3.9: The World CDx Market Share (%) in the IVD Market, 2026
  • Figure 3.10: The CDx Market: Market Shares (%) by Sector in the IVD Market, 2014
  • Figure 4.1: The Leading National Markets for CDx by Sales ($bn), 2014
  • Figure 4.2: The Leading National Markets for CDx by Market Share (%), 2014
  • Figure 4.3: The Leading National Markets for CDx by Market Share (%), 2020
  • Figure 4.4: The Leading National Markets for CDx by Market Share (%), 2026
  • Figure 4.5: The US CDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 4.6: The EU5 Leading National Markets for CDx by Revenue ($bn), 2014
  • Figure 4.7: The EU5 Leading National Markets for CDx by Market Share (%), 2014
  • Figure 4.8: The EU5 National Markets for CDx by Market Share (%), 2020
  • Figure 4.9: The EU5 National Markets for CDx by Market Share (%), 2026
  • Figure 4.10: The German CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 4.11: The French CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 4.12: The Italian CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 4.13: The Spanish CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 4.14: The UK CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 4.15: The Japanese CDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
  • Figure 4.16: The Chinese CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 4.17: The Indian CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 4.18: The Brazilian CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 4.19: The Russian CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 4.20: The South Korean CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 4.21: The Rest of the World CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
  • Figure 6.1: Current Business Models for the Development of Companion Diagnostics, 2016
  • Figure 6.2: Stakeholders in the Companion Diagnostics Market, 2016
  • Figure 7.1: Roche Diagnostics: Revenues ($bn) by Business Area, 2014
  • Figure 7.2: Roche Diagnostics: Revenue Share (%) by Business Area, 2014
  • Figure 7.3: Roche Diagnostics: Revenue Share (%) by Geography, 2014
  • Figure 7.4: Qiagen: Revenue ($bn), Net Income ($bn) and Profit Margin (%), 2010-2015
  • Figure 7.5: Qiagen: Revenue Share (%) by Geography, 2015
  • Figure 7.6: Abbott Laboratories: Historical Revenue ($m), 2012-2015
  • Figure 7.7: Abbott Laboratories: Revenue Share (%) by Business Sector, 2015
  • Figure 7.8: Agilent Technologies: Revenue ($bn) by Business Segment 2013-2015
  • Figure 7.9: Myriad Genetics: Revenue ($m), Net Income ($m) and Profit Margin (%), 2011-2013
  • Figure 7.10: bioMérieux: Revenue ($bn) and AGR (%), 2010-2015
  • Figure 7.11: bioMérieux: Revenue ($bn) by Region, 2014
  • Figure 7.12: bioMérieux: Revenue Share (%) by Region, 2015
  • Figure 7.13: bioMérieux: Revenue Share (%) by Technology, 2015
  • Figure 7.14: Thermo Fisher Scientific: Revenue Sales ($bn) by Business Sector, 2015
  • Figure 7.15: Thermo Fisher Scientific: Revenue Share (%) by Geography, 2015
  • Figure 8.1: Drivers and Restraints in the Companion Diagnostics Market, 2016-2026
  • Figure 8.2: Porter's Five Analysis of the Companion Diagnostics Market, 2016-2026
  • Figure 9.1: Theranostics and Other In Vitro Diagnostics: World Sales Forecast ($bn), 2014, 2020 and 2026

Companies Listed

  • 20/20 Gene Systems
  • Abbott Laboratories
  • Abbott Molecular
  • AbbVie
  • Advanced Scientifics
  • Affymetrix
  • Agilent Technologies
  • Alere
  • Alfa Aesar
  • Almac
  • Ambry Genetics
  • Amgen
  • Arca Biopharma
  • Argene
  • Ariosa Diagnostics
  • Arno
  • Astellas Pharma
  • AstraZeneca
  • Astute Medical
  • Asuragen
  • AviaraDx
  • Bayer
  • Bina Technologies,
  • Biocartis
  • Biofire Diagnostics
  • bioMerieux
  • Biomonitor
  • Boehringer Ingleheim
  • Bristol Myers-Squi
  • CAPP Medical
  • Caprion Proteomics
  • Caris Life Sciences
  • Celera (Quest Diagnostics)
  • Celgene
  • Cepheid
  • Clarient
  • Clinical Regerence Laboratory
  • Clovis Oncology
  • CompanDx
  • Crescendo Bioscience
  • Curidium Medica
  • Dako (Agilent Technologies)
  • DiagnoCUr
  • Dutalys
  • Dx Assays
  • Eli Lilly
  • Endocyte
  • Epizyme
  • Exosome Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • Ferring Pharmaceuticals
  • Flagship Biosciences
  • FlowMetric Diagnostics
  • Foundation Medicine
  • GE
  • Genentech
  • GENEWEAVE Biosciences, Inc.
  • Genfit
  • Genia Technologies, Inc.
  • Genmab
  • Genmark Diagnostics
  • Gilead Sciences
  • GlaxoSmithKline
  • Hexie Health
  • HistologiX
  • Idera Pharmaceutical
  • IGEN International
  • Ilumina
  • ImmunoGen
  • Incyte
  • InDex Pharmaceuticals
  • Institut Merieux
  • Inverness Medical Innovations
  • Invivoscribe Technologies
  • Ipsen
  • Ipsogen
  • IQuum, Inc.
  • Johnson Matthey Plc
  • Kapa Biosystems
  • Keysight Technologies
  • Kimball Genetics
  • Kunlun Health Insurance
  • Lab 21
  • Lab Corp.
  • Leica Biosystems
  • Leica Microsystems
  • Life Technologies
  • Luminex
  • MedImmune
  • Merck & Co.
  • Merck KGaA
  • Merck Serono
  • Molecular MD
  • Myriad Genetics
  • Nanosphere
  • Nanostring
  • NIH
  • Novartis
  • Origin Technologies Corp.
  • OSI Pharmaceuticals
  • Oxford BioTherapeutics
  • Pfizer
  • PICC Health Insurance
  • Ping An Insurance Group
  • PrimeraDx
  • Prionics
  • Progenika Biopharma
  • Prometheus
  • Protagen
  • Qiagen N.V.
  • Quest Diagnostics
  • Quintiles Transnational Corporation
  • Randox Pharma Services
  • RAS Lifesciences Pvt. Ltd
  • RiboMed Biotechnologies
  • Saladax Biomedical
  • Santaris Pharma A/S
  • Seragon Pharmaceuticals
  • Siemens Healthcare
  • Signature Diagnostics AG
  • Sirius Genomics
  • Synthon Biopharmaceuticals
  • Sysmex Inostics
  • Takeda Pharmaceuticals
  • Target Discovery
  • TcLand Expression
  • TESARO
  • Theranostics
  • Thermo Fisher Scientific
  • Third Wave Technologies
  • TIB MOLBiol
  • Tragara Pharmaceuticals
  • Transgenomic
  • TrimGEn Crorporation
  • Trophos
  • Unilabs
  • Ventana Medical Systems (Roche)
  • Weisenthal Cancer Group

Organisations Mentioned in the Report

  • Cancer Research UK
  • Center for Medicaid and CHIP Services
  • European Medicines Agency (EMA)
  • Hauté Autorite de Santé
  • National Health Insurance (South Korea)
  • Pharmaceutical and Medical Devices Agency (PMDA) (Japan)
  • Servizio Sanitario Nazionale
  • Sistema Único de Saúde (SUS)
  • The Association of British Pharmaceutical Industries
  • The Japanese Ministry of Health, Labour and Welfare
  • The Medical Research Council (UK)
  • The National Health Service (NHS)
  • The National Institute of Clinical Excellence (NICE)
  • The Office of In Vitro Diagnostic Device Evaluation and Safety
  • TRICARE
  • Tufts Center for the Study of Drug Development
  • US Food and Drug Agency (FDA)
Back to Top